U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C35H56N6O5
Molecular Weight 640.8563
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEMADOTIN

SMILES

CC(C)[C@H](NC(=O)[C@H](C(C)C)N(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC3=CC=CC=C3

InChI

InChIKey=XSAKVDNHFRWJKS-IIZANFQQSA-N
InChI=1S/C35H56N6O5/c1-22(2)28(37-32(43)29(23(3)4)38(7)8)34(45)39(9)30(24(5)6)35(46)41-20-14-18-27(41)33(44)40-19-13-17-26(40)31(42)36-21-25-15-11-10-12-16-25/h10-12,15-16,22-24,26-30H,13-14,17-21H2,1-9H3,(H,36,42)(H,37,43)/t26-,27-,28-,29-,30-/m0/s1

HIDE SMILES / InChI
Molecular Formula C35H56N6O5
Molecular Weight 640.8563
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/9860873 | http://adisinsight.springer.com/drugs/800006853

Cemadotin (LU103793) is a cytotoxic water-soluble pentapeptide analogue of dolastatin 15. The dolastatin peptides were originally isolated from the shell-less mollusc Dolabella auricularia. Cemadotin blocks cells at mitosis. It exerts its antitumor activity by suppressing spindle microtubule dynamics through a distinct molecular mechanism by binding at a novel site in tubulin. Cemadotin was in phase II clinical trials as a promising cancer chemotherapeutic agent. However, this agent appears to be inactive in the treatment of advanced non-small-cell lung cancer and other tumors and this research has been discontinued.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Tubulin
69
Target ID: CHEMBL2094134
Inhibitor
8504
 19.4 µM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.2 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9704730
3 mg/m² 1 times / day steady-state, intravenous
dose: 3 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
CEMADOTIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.75 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9704730
2.5 mg/m² single, intravenous
dose: 2.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEMADOTIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.97 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9704730
2.5 mg/m² 1 times / day steady-state, intravenous
dose: 2.5 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
CEMADOTIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.3 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9704730
3 mg/m² 1 times / day steady-state, intravenous
dose: 3 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
CEMADOTIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.1 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9704730
2.5 mg/m² single, intravenous
dose: 2.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEMADOTIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.5 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9704730
2.5 mg/m² 1 times / day steady-state, intravenous
dose: 2.5 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
CEMADOTIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9704730
3 mg/m² 1 times / day steady-state, intravenous
dose: 3 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
CEMADOTIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
13 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9704730
2.5 mg/m² single, intravenous
dose: 2.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEMADOTIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9704730
2.5 mg/m² 1 times / day steady-state, intravenous
dose: 2.5 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
CEMADOTIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
17.5 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 17.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 17.5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (grade 4, 100%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
12.5 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 12.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 12.5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (grade 4, 16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
2.5 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 2.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
DLT: Neutropenic fever...
Dose limiting toxicities:
Neutropenic fever (grade 3, 8.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
3 mg/m2 1 times / day multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (66.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
AEs

AEs

AESignificanceDosePopulation
Neutropenia grade 4, 100%
DLT
17.5 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 17.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 17.5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
Neutropenia grade 4, 16.7%
DLT
12.5 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 12.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 12.5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/11052630
Neutropenic fever grade 3, 8.3%
DLT
2.5 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 2.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
Neutropenia 66.7%
DLT
3 mg/m2 1 times / day multiple, intravenous
Studied dose
Dose: 3 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/9704730
Sourcing

Sourcing

Vendor/AggregatorIDURL
BOC Sciences
159776-69-9
http://www.bocsci.com/description.asp?cas=159776-69-9
eMolecules
110064454
https://orderbb.emolecules.com/search/#?query=110064454
MuseChem
R060089
https://www.musechem.com/product/R060089.html
PubMed

PubMed

TitleDatePubMed
Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action.
1998-12-15
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society.
1998-12
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
1998-08
LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis.
1995-07-15
Patents

Patents

20010044451
27
JP2007509861A
8
JP2007538099A
19
JP4806680B2
7

Sample Use Guides

In Vivo Use Guide
2.5 mg/m2 as a 5-minute infusion for 5 consecutive days every 3 weeks
Route of Administration: Intravenous
In Vitro Use Guide
Turbidity assays with bovine brain microtubules demonstrated that LU103793 inhibits microtubule polymerization in a concentration-dependent manner (IC50 = 7 uM).
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:45:39 GMT 2025
Edited
by admin
on Wed Apr 02 08:45:39 GMT 2025
Record UNII
6SQ8M7ZSFV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NSC-D-669356
Preferred Name English
CEMADOTIN
INN   WHO-DD  
INN  
Official Name English
cemadotin [INN]
Common Name English
Cemadotin [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67422
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
Code System Code Type Description
SMS_ID
100000082045
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
PUBCHEM
9812632
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
NCI_THESAURUS
C75875
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
INN
7399
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
FDA UNII
6SQ8M7ZSFV
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
CAS
159776-69-9
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
ChEMBL
CHEMBL2104387
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
EPA CompTox
DTXSID70166723
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
EVMPD
SUB07438MIG
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
MESH
C094621
Created by admin on Wed Apr 02 08:45:39 GMT 2025 , Edited by admin on Wed Apr 02 08:45:39 GMT 2025
PRIMARY
Related Record Type Details
Structure of CEMADOTIN HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of DOLASTATIN 15
PARENT -> DERIVATIVE
Related Record Type Details
Structure of CEMADOTIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966